Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05585814 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

Study acronym: COBP
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Study completion moved earlier from May 1, 2028 to May 9, 2027
    • Primary completion date: Oct 1, 2024 to Sep 18, 2024
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 9 more changesShow less
    • Enrollment target: 12 to 30
    • Primary completion date changed from estimate of Mar 2023 to Oct 1, 2024
    • Start date changed from estimate of Oct 2022 to May 1, 2023
    • Primary endpoints: 3 to 4
    • Study sites: 0 to 1
    • Study completion date: Oct 2025 to May 1, 2028
    • Eligibility criteria shortened, about 9 words
    • Secondary endpoints revised (7)
    • Study title expanded, about 2 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective, single-arm study aims to investigate the efficacy and safety of pembrolizumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS locally advanced rectal cancer patients
Trial Details
NCT Number NCT05585814
Lead Sponsor Shanghai Changzheng Hospital
Conditions
(from sponsor)		 Locally Advanced Rectal Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov